Peter Vranes, Nutromics - Continuous Diagnotic Monitoring | LSI Europe '22

Transcription

Peter Vranes  0:03  

My name is Peter Vranes. I'm the co-founder, CEO of Nutromics. Were a diagnostic medical device company. And we exist to save millions of lives through continuous diagnostic monitoring. So the problem that we're tackling is that clinicians are making life and death decisions in the dark. And that's because they're hampered by insufficient and delayed lab diagnostics. Now, let me tell you take you through basically how lab diagnostics are done in simple terms. So a clinician orders it tests, a blood draw is taken, that sample is then delivered to the lab. It's analyzed in the lab. And then the Cushing gets a single data point of where that patient was several hours ago. Now in the ICU setting where commonly trend information is required, that process needs to be repeated multiple times. And in reality, that rarely happens. It's just impractical. And incredibly 70% of all clinical decisions are based on this process. And the outcome, as you can imagine, is that it cost patients their lives, and it costs billions of dollars in inefficiency in the hospital system. So our solution is a wearable diagnostic what I have in my hand that provides continuous and real time diagnostic monitoring. So instead of one data point that the clinician receives several hours ago, they will now receive with this device 1000s of data points, giving them critical trend information to improve patient outcomes. Now this, this device replaces the blood draw the sample delivery to the lab, and the analysis in the lab. And in effect, it's what we call a lab on a patch, because all of that is done on this patch. And for the first time clinicians will receive personalized, patient centric insights to improve patient outcomes save lives, and billions of dollars in improved hospital efficiency. So the technology is comprised of a DNA sensor platform, that is a sensing platform that can monitor any molecular target continuously and in real time. And what we do is we coat these little micro needles that you can see on that screen, they're very small, about one millimeter with this DNA sensor. So each micro needle has a different sensor coded on the end. And what we can do is multi analyte sensing. So we can stream multiple sensors, multiple targets, in parallel. That's unprecedented in the industry in the industry. So this technology is highly differentiated. For any technology to play in this place, it has to do two things. It needs to be a platform technology that can monitor any molecular target. And it needs to be proven to work on body. And our DNA sensor is the only one that is both a platform technology, and proven to work on body which is very exciting. Now we often get compared to continuous glucose monitors, that technology has revolutionized type one diabetes, and also moving now into type two diabetes. And we are the evolution of that technology. And there's two reasons for that. So CGM is are based on enzymatic sensing. And that's not a platform, our DNA technology is a platform. This timeline tells a story. So in the last 40 years, there's only ever been five Intermatic sensors that have been developed and shown to work on body. Now compare that to our DNA sensing platform. In the last five years, we've developed more than a dozen sensors, and showing them to work on body more than doubling what the whole Intermatic industry took 40 years to do. That's the power of a platform. Secondly, those five senses are all metabolites, things endogenous in our body, that's the class that you can do with enzymatic sensing. We can do metabolites. But we can also do drugs, proteins, hormones, meaning we can go into Blue Ocean Territory when no other technology can compete. Now, I don't want you to think that this is just aspirational. We have 10 Peer Reviewed papers, showing that this technology works on body. So if you can solve if you can monitor any molecular target continuously and in real time, what problems in healthcare can you solve? That's the question that we've been posing for quite some time. And we went back to the reason that we exist as a company that's to save lives. So we're going after some of the deadliest disease states in the world. That includes cardiovascular disease, acute kidney injury, sepsis, and therapeutic drug monitoring that goes across all of these This disease states. So our first market is therapeutic drug monitoring of the antibiotic vancomycin, very commonly dose one in five of all inpatients in US hospitals get this drug. However, it has a very narrow therapeutic window and high toxicity. And clinicians get very limited data to get patients into that therapeutic zone. The outcome of this is that 43% of patients get a vancomycin induced Aki, one of the top 10 kills in the hospital with a mortality rate of 33%. In the acute setting, we can we started here, because we can have a huge impact in this market straightaway. So instead of three data points over 36 hours is, which is what clinicians get Now, with this technology, this device, they will get 1000s of data points continuously and in real time. So it's the equivalent of taking the blindfold off. And their ability to get a patient in the therapeutic zone, keep them out of the toxic zone is greatly enhanced. So in the US, the TAM for our first product is $4 billion. And that's comprised of 6 million patients getting vancomycin every year, for an average of eight days, with a patch cost of $80. That's a replacement IV the cost of the current system now. Now, beyond VANK, bound our first market vancomycin, we're going further down the TDM, vertical with other targets such as immediate glycosides. Now remember, I'm talking about one device here, each of these new indications is on the same device. This is not different devices. That's horizon one, Horizon two is where we go, where we increase the number of sensors. So that's increased the number of needles and sensors on each needle on the same device to go after acute kidney injury. That's where we're monitoring things like creating and other markers. It's one of the top 10 killers in hospital sepsis. It's a fast moving disease that perfectly suited to continuous real time monitoring. Sepsis kills 12 million people every year, and are what we call our blockbuster market, cardiovascular disease. That's where we're monitoring troponin and other high value targets. And then horizon three is where we go where we increase the number of sensors on the same patch. And we go for a patch for every patient, because regardless of the patient's journey through the hospital system, and out of the hospital system through remote patient monitoring, will have clinical utility. For horizon 2 the TAM is large, obviously, it's over $70 billion in the US alone. So the Alpha prototype that I have here, and if you would like Laddie can come and have a look at it. It's been developing rapidly. We're in first in human trials at the moment, and we're looking to launch the device in 2026. We're developing our manufacturing facility that will be able to produce 100 million of these devices every year. We have a 10,000 square foot r&d facility in Melbourne. And we do r&d Also in San Diego. So far, we have raised $20 million. We we did an announcement a couple of weeks ago of a $14 million raise led by Dexcom. So then one of the leaders in CGM, and next year, we're heading to a 50 to $100 million raise. Our team is experienced and passionate about what we do. The team's mainly based in Australia, but increasingly were increasing our numbers in the US I have Bashiry, our chief medical officer here as well today. So we're happy to have a chat with you. But we have deep experience in med tech diagnostics and manufacturing. And I'm just about out of time, and I'm wrapping up. So every year means that people die because clinicians lack continuous real time diagnostic monitoring capabilities. And we exist as a company to create a world with zero preventable deaths through continuous and real time diagnostic monitoring. Thank you